April 7, 2025 06:26 AM EDTUpdated 06:38 AM
Cell/Gene Tx
Manufacturing

Cell and gene ther­a­py CD­MO Am­pli­fy­Bio shuts down over 's­carci­ty' of fund­ing

Anna Brown

News Reporter

An­oth­er CD­MO has been hit by the slow­down of cell and gene ther­a­py R&D.

Am­pli­fy­Bio closed its doors af­ter strug­gling for months to find in­vestor …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Stock mar­ket melts down over Trump’s tar­iffs, and biotech's pain keeps grow­ing

GSK’s newest neu­ro pact is with ABL Bio, a Sanofi-part­nered South Ko­re­an biotech

Rhythm touts Phase 3 win for rare obe­si­ty drug in peo­ple with brain dam­age

Im­munol­o­gy start­up RayThera se­cures $110M in Se­ries A raise

Q&A: David Liu talks about sci­ence un­der pres­sure, teas­es “dis­ease-ag­nos­tic” gene edit­ing

Q&A: A con­ver­sa­tion with GLP-1 co-dis­cov­er­er Jens Ju­ul Holst on the fu­ture of in­cretin-based drugs

A service from the Financial Times